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Abstract
Temporal lobe epilepsy (TLE) is a common epilepsy syndrome with a complex etiology. Despite evidence for the participation
of genetic factors, the genetic basis of TLE remains largely unknown. A role for the galanin neuropeptide in the regulation of
epileptic seizures has been established in animal models more than two decades ago. However, until now there was no report
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of pathogenicmutations inGAL, the galanin-encoding gene, and therefore its role in human epilepsywas not established. Here,
we studied a family with a pair of monozygotic twins affected by TLE and two unaffected siblings born to healthy parents.
Exome sequencing revealed that both twins carried a novel de novo mutation (p.A39E) in the GAL gene. Functional analysis
revealed that the p.A39E mutant showed antagonistic activity against galanin receptor 1 (GalR1)-mediated response, and
decreased bindingafﬁnityand reducedagonist properties for GalR2. Theseﬁndings suggest that thep.A39Emutant could impair
galanin signaling in the hippocampus, leading to increased glutamatergic excitation and ultimately to TLE. In a cohort of 582
cases, we did not observe any pathogenicmutations indicating thatmutations in GAL are a rare cause of TLE. The identiﬁcation
of a novel de novomutation in a biologically-relevant candidate gene, coupledwith functional evidence that themutant protein
disrupts galanin signaling, strongly supports GAL as the causal gene for the TLE in this family. Given the availability of galanin
agonists which inhibit seizures, our ﬁndings could potentially have direct implications for the development of anti-epileptic
treatment.
Introduction
Temporal lobe epilepsy (TLE) is the most common partial epi-
lepsy in adults (1). Originally considered as an acquired condi-
tion, twin studies and the description of familial forms have
demonstrated the importance of genetic factors in TLE (2,3). Up
to date, two genes (LGI1 and DEPDC5) have been found mutated
in familial temporal lobe epilepsies; the LGI1 gene (leucine-rich,
glioma inactivated 1) has been found mutated in autosomal
dominant lateral temporal lobe epilepsy (ADTLE), and these mu-
tations lead to failure of glutamate re-uptake resulting in ele-
vated glutamate concentration and increased activation of
NMDA receptors in the pyramidal neurons, causing epileptic sei-
zures (4). Recently, the DEPDC5 gene (dishvelled, Egl-10 and
pleckstrin domain-containing protein 5) has been foundmutated
in familial partial epilepsy with variable foci (FPEVF) (5). DEPDC5
is part of the GATOR complex and negatively regulates the mTOR
pathway which controls numerous functions including cellular
proliferation, protein synthesis, and transcription (6).
The galanin neuropeptide was discovered more than 30 years
ago and described as being able to contract smooth muscle and
cause hyperglycemia (7). Galanin is 30-amino-acid peptide
produced from the cleavage of a 123-amino-acid protein precur-
sor encoded by the galanin/GMAP prepropeptide gene (GAL;
NM_015973.3). The GAL gene contains 5 coding exons among
which exons 2 and 3 encode for galanin. The galanin neuro-
peptide acts as a cellular messenger within the central and per-
ipheral nervous systems, modulating diverse physiological
functions (8). In 1992, Mazarati and collaborators ﬁrst demon-
strated that galanin has anticonvulsivant activity in rodents (9).
Over the past two decades, signiﬁcant progress has been made
in the understanding of the role of galanin as an endogenous in-
hibitor of epileptic activity as well as in deciphering the involve-
ment of three G-protein-coupled galanin receptors (GalR1, 2 and 3).
Galanin, which is highly expressed in the hippocampus, exerts
an inhibitory effect on glutamatergic transmission through the
activation of GalR1 and GalR2, ultimately inhibiting epileptic sei-
zures (10). The anticonvulsivant effects of galanin have prompted
the development of agonists as well as encapsulated galanin-
producing cells in the prospect of designing galanin-based anti-
epileptic strategy (11,12). Despite all the past knowledge and
advanced understanding of the anticonvulsivant properties of
galanin, there has not been yet any evidence for pathogenic mu-
tations in the human galanin gene related to epilepsy.
Here, we report on the identiﬁcation of a missense mutation
(p.A39E) in exon 2 of the GAL gene, which encodes for galanin,
in patients with TLE.We have shown that this galaninmutant af-
fects galanin binding to receptors and downstream signaling and
may ultimately lead to TLE. The results of our study further
strengthen the role of galanin in epilepsy and could have direct
implications for patient care.
Results
Exome sequencing data
Whole exome sequencing was carried out on the parents–child
trio (individuals I-1, I-2 and II-3; Fig. 1). On average, we produced
262 (±9.3 SD) million reads per sample, 255 (±8.8 SD) million were
properly paired and mapped uniquely to the reference genome
(hg19), 233 (±8.2 SD) million reads remained after removal of du-
plicate reads, and among these, 165 (±5.3 SD)million were on tar-
get. This resulted in an average coverage of at least 8× for 97.43%
(±0.04 SD) of the coding part of the RefSeq genes. An average of
27 412 (±210 SD) variants was detected per individual. Supple-
mentary Material, Table S1 provides a summary of the exome se-
quencing results for each individual.
Identiﬁcation of de novo and recessive variants
In the absence of positive family history of seizures or other
neurological manifestations, we hypothesized that the affected
monozygotic twinswere sporadic cases and looked for pathogen-
ic de novomutations in onememberof the twin pair (individual II-
3). We identiﬁed 2 de novo single nucleotide variants (SNVs)
(Table 1). All small insertions/deletions (indels) classiﬁed as de
novowere rejected during visual inspectionmainly due tomiscal-
ling of indels in homopolymer tracts or trinucleotide repeats
(data not shown). The ﬁrst de novo SNV resulted in an aspartic
acid to glycine change at position 137 of the cysteine-rich secre-
tory protein LCCL domain-containing 2 precursor (CRISPLD2)
gene (c.A410G; p.D137G). The second variant caused an alanine
to glutamic acid substitution at position 39 of the galanin/
GMAP prepropeptide (GAL) gene (c.C116A; p.A39E). These two
variants were novel, not present in dbSNPv138 nor in the
ExomeAggregation Consortium (ExAC) database andwere classi-
ﬁed as damaging by SIFT, Polyphen2 and Mutation taster
(Table 1). Up to date, CRISPLD2 has never been associated with
seizures or epilepsy but with non-syndromic cleft lip with or
without cleft palate in several studies (13–15) except for one
(16). The unaffected sister (II-1) did not carry this variant. How-
ever, as none of the twins presented with this condition, this
gene was not further considered.
We also investigated the possibility of a recessive model and
looked for the presence of homozygote or compound heterozy-
gote mutations in the twins. We identiﬁed three genes (BCR,
MYO9A and SH3TC1) with mutations compatible with an
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autosomal recessivemode of inheritance (SupplementaryMater-
ial, Table S2). However, none of these genes has been linked to
epilepsy. The BCR gene is the site of breakpoints used in the gen-
eration of the 2 alternative forms of the Philadelphia chromo-
some translocation found in chronic myeloid leukemia and
acute lymphocytic leukemia (OMIM#151410). The MYO9A and
SH3TC1 genes have not been associated with disorders. These
genes were not further considered.
The galanin neuropeptide was found to act as a potent antic-
onvulsivant and regulate epileptic seizures in animalmodels (17,
for review). However, until now its role in human epilepsy was
not established. All familymemberswere subsequently screened
for the p.(A39E) mutation using Sanger sequencing. We con-
ﬁrmed the wild-type allele in both parents and the unaffected
sister and the mutated allele in both affected twins (Fig. 1).
The 30-amino-acid galanin is located at position 33 to 62 of
the 123-amino-acid galanin/GMAP prepropeptide which also
comprises a 5′-hydrophobic signal peptide and a 3′-galanin mes-
sage-associated peptide (GMAP). These peptides are released
upon cleavage at two Lysine-Arginine (KR) dibasic sites located
on either side of galanin (18). The p.(A39E) mutation affects the
alanine at position 39 of the GAL prepropeptide (galanin precur-
sor), which corresponds to the 7th residue of the 30-amino-acid
mature galanin peptide. Theﬁrst 15 residues of galanin arehighly
conserved throughout evolution and crucial for its biological ac-
tivity (Fig. 2). The last 15 residues, which are less conserved, lack
receptor afﬁnity and are believed to protect the C-terminal half
from proteolysis (19–21).
Screening of the GAL gene for mutations in patients
with focal epilepsy (FE)
To further appreciate the contribution of galaninmutations in FE
in humans,we performedmutation analysis of coding sequences
and splice site junctions of exons 2 and 3 of the GAL gene, which
encode for the galanin neuropeptide, in 530 individuals with TLE
and 52 patients with various types of focal epilepsies. We also
analyzed exon 1 to seek for potential nonsense and frameshift
mutations. We did not ﬁnd any potential pathogenic mutations
suggesting that GAL mutations are a rare cause of TLE.
Figure 1. Pedigree structure of family EPI-ORA-AFF. Sanger sequencing traces showing the c.C116A (p.A39E)mutation in exon 2 of the GAL gene. The black arrows indicate
the variant present in both affected twins (II-3 and II-4).
Table 1. List of validated de novo variants
Chr Position Gene (Acc. number) Nucl. change AA change Cov.a SIFT PP2 MT GERP
11 68’453’096 GAL (NM_015973.3) c.C116A p.A39E 370 0 0.93 0.98 2.45
16 84’883’042 CRISPLD2 (NM_031476.3) c.A410G p.D137G 140 0.02 0.99 0.99 5.03
SIFT, Sorting Intolerant from Tolerant algorithm; PP2, Polyphen2; MT, MutationTaster; GERP, Genomic Evolutionary Rate Proﬁling score.
Cov.a: Number of reads after the removal of duplicates that covers this position.
DP4#: Number of reads after the removal of duplicates that supports from left to right: forward reference allele—reverse reference allele—forward mutant allele—reverse
mutant allele. Sum can be smaller than coverage because low-quality bases are not counted.
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Functional analysis of the p.(A39E) mutation
Galanin-receptor afﬁnity analysis
Displacement studies of 125I-galanin with hGal(WT) or hGal
(A39E) peptides, were performed on cellmembranes fromhuman
Bowes melanoma cells endogenously expressing human GalR1
(hGalR1), CHO cells stably transfected with human GalR2
(hGalR2) and ﬁnally Flp-In T-REx 293 cells with inducible expres-
sion of human GalR3 (hGalR3). When compared to that of hGal
(WT), hGal(A39E) peptide showed similar binding afﬁnities to
hGalR1 (t-test two-tailed P-value = 0.25) and hGalR3 (t-test two-
tailed; P-value = 0.10) but signiﬁcantly decreased afﬁnities to
hGalR2 (t-test two-tailed P-value = 0.03; Fig. 3 and Table 2). hGal
(A39E) peptide also showed preferred binding to hGalR1 with a
8-fold selectivity when compared to hGalR2 and 259-fold select-
ivity when compared to hGalR3 (Table 2).
Galanin signaling analysis
Bowes cells expressing hGalR1 were pre-incubated with increas-
ing concentrations of hGal(A39E) peptide (from 0.1 n to 10 μ)
for 1 h before being stimulated with 100 n hGal(WT). Cell
index was monitored before and after the addition of the pep-
tides. hGal(WT) peptide showed a half maximal effective
Figure 2. Multiple species alignment of the predicted amino-acid sequences of the galanin peptide and ﬂanking cleavage sites produced using the 100-way multiZ new
(hg19) option in Galaxy (https://usegalaxy.org/). Theﬂanking dibasic Arg-lys (KR) cleavage sites aredepicted in green. Red arrows point to the residue foundmutated in TLE
patients (p.A39E).
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concentration (EC50) value of 22.4 ± 2.56 n (Fig. 4). hGal(A39E)
peptide exhibited a dose-dependent inhibition of the hGal(WT)
response, with an half maximal inhibitory concentration (IC50)
value of 486.5 ± 12.46 n, suggesting that hGal(A39E) acts as an
antagonist of galanin GalR1-mediated signaling (Fig. 4).
Signal transduction was examined by assessing the ability to
stimulate inositol phosphate (IP) production in CHO cells expres-
sing hGalR2. Both hGal(WT) and hGal(A39E) peptides stimulated
IP production (Fig. 5). hGal(WT) stimulated IP production with a
EC50 value of 171 ± 9.37 n, whereas hGal(A39E) showed a statis-
tically signiﬁcant higher EC50 value of 1243 ± 103 n (t-test two-
tailed, P-value = 0.0005) indicating that this mutant is a 7-fold
less potent activator of hGalR2 (Fig. 5). The additive effect of dif-
ferent concentrations of hGal(A39E) on IP production obtained
with 100 n hGal(WT) was also assessed. hGal(A39E) showed a
statistically signiﬁcant additive effect starting from concentra-
tion of 1 μ (one-way ANOVA, P-value < 0.001; Fig. 6). Indeed, an
increase in IP production was observed when CHO cells were
co-stimulatedwith hGal(WT) andhGal(A39E) compared to stimu-
lation with hGal(WT) alone suggesting that hGal(A39E) acts as a
hGalR2 agonist (Fig. 6). hGal(A39E) at concentration below than
1 μ did not show signiﬁcant synergistic effect on the IP produc-
tion induced by 100 n hGAL(WT) (Fig. 6).
Discussion
Here, we report on the identiﬁcation of a de novo p.(A39E) muta-
tion in the galanin/GMAP prepropeptide (GAL) gene in a family
with TLE. The GAL gene encodes for the galanin neuropeptide
which possesses anticonvulsant activities in animal models.
Functional analysis of the mutant galanin peptide showed that
it impairs galanin function in a dominant negative manner.
A role of galanin in epilepsy was ﬁrst demonstrated 22 years
ago by Mazarati and collaborators who showed that galanin de-
creased the severity of picrotoxin-kindled convulsions in rats
and that seizures-induced galanin depletion may contribute to
the maintenance of seizure activity, whereas the increase of ga-
lanin concentration may favor the cessation of seizures (9,22). In
addition, transgenic mice that overexpress galanin showed in-
creased resistance to seizure induction, whereas mice deﬁcient
for galanin showed higher seizure susceptibility (23). Galanin eli-
cits a range of biological effects by interactions with three G-pro-
tein-coupled receptors (GalR). Both GalR1 and GalR2, which are
expressed in the hippocampus, mediate anticonvulsivant effect
of galanin (24). GalR3, which is mainly expressed in the preop-
tic/hypothalamic area, has not been reported to play a role in epi-
lepsy (25). The hippocampal formation, which is involved in
seizures underlying TLE, receives galaninergic and excitatory
glutamatergic innervations. Galanin ﬁbers suppress this excita-
tory action through the opening of potassium channel which
triggers membrane hyperpolarization and eventually inhibits
glutamate release from presynaptic terminals (26). Our data on
the function of the p.A39E mutant are consistent with this
model; indeed, the p.A39E mutant, which has been shown to re-
duce galanin signaling, is predicted to increase neuronal excit-
ability in the hippocampus, ultimately leading to TLE. The
discovery of galanin mutations suggests that genetic variation
in galanin may be important in TLE.
Analysis of GAL formutations in 530 individuals with TLE and
52 patients with various types of focal epilepsies did not reveal
additional pathogenic mutations indicating that galanin muta-
tions are not important contributors to the genetics of TLE. How-
ever, mutation screening of other genes involved in galanin
signaling, for instance the galanin receptors, would be necessary
to comprehensively assess the contribution of galaninergic sys-
tem to the genetics of TLE. Indeed, GalR1 has been shown to ex-
acerbate hippocampal neuronal loss after status epilepticus (27)
and CYM2503, a GalR2-positive allosteric modulator, has been
shown to exhibit anticonvulsant effects in animal models (11).
Seventy two missense and loss-of-function mutations in the
galanin/GMAP prepropeptide (GAL) gene have been reported by
ExAC (http://exac.broadinstitute.org/). Among these mutations,
only ten were predicted to affect galanin synthesis and/or
Figure 3. Galanin-receptors binding studies: Displacement of porcine-[125I]-
galanin from membranes by peptide hGal(WT) (A) or hGal(A39E) (B).
Membranes were from human Bowes melanoma cells expressing GalR1 (closed
circle), CHO cells expressing GalR2 (closed square) and Flp-InT-REx 293 cells
expressing GalR3 (closed triangle). The data are from three representative
experiments performed in duplicates, presented as mean ± SEM.
Table 2. Ki values of hGal(WT) and hGal(A39E) towards galanin receptors 1, 2 and 3 (GalR1, 2 and 3)
Ki (nM; mean ± SEM)
Ligand GalR1 GalR2 GalR3 Ki GalR2/
Ki GalR1
Ki GalR3/
Ki GalR1
hGal(WT) 6.071 ± 2.134 1.789 ± 0.684 80.90 ± 27.08 0.29 13.32
hGal(A39E) 3.001 ± 0.848 24.90 ± 7.01 780 ± 337 8.29 259.91
P-value (t-test) 0.252 0.03 0.1
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function including six loss-of-function mutations and four mis-
sense mutations (Supplementary Material, Table S3). For in-
stance, the p.Trp25leufsTer47 frameshift mutation is predicted
to disrupt the synthesis of the galanin peptide which is located
at position 33 to 62 of the 123-amino-acid galanin/GMAP prepro-
peptide. The other variants in the galanin/GMAP prepropeptide
were missense mutations located in exons which do not encode
for galanin andwere therefore unlikely to affect galanin function.
The pathogenic signiﬁcance of these 10 variants is currently un-
known as (i) there is no experimental data on their potential ef-
fect on galanin function and (ii) the phenotypic status of the
carriers is not available. Even if considering that they are all
pathogenic, their cumulative allele frequency was calculated at
0.0246% which is well-below the prevalence of TLE estimated at
0.17% (28). Our functional analysis of the hGal(A39E) mutant fa-
vored dominant negative effect over haploinsufﬁciency as a po-
tential mechanism for causation. Among the ten variants
predicted to affect galanin, the missense mutations are most
likely to act in a dominant negative manner. Their cumulative
frequency was calculated at 0.0075% which is compatible with
their involvement as a very rare cause of TLE.
The anticonvulsivant effects of galanin have prompted the
development of various approaches targeting the galanin system
for the treatment of epilepsy. For example, Lu et al. (11) have de-
veloped a GalR2-positive allosteric modulator, which potentiates
the galanin action. Rodents with induced seizures that had re-
ceived this compound showed increased seizures threshold and
reduced seizures duration. The p.A39E mutant, which showed
antagonist effects on GalR1 and reduced agonist effects on
GalR2, is likely to have direct implications for the development
of galanin-based anti-epileptic molecules.
Materials and Methods
Monozygotic twins with TLE
Monozygotic twins affected by TLE, born to healthy and non-con-
sanguineous parents, were evaluated by one of the authors (AC)
at the Neurology Department of Oran University Hospital (Al-
geria) (Fig. 1). Clinical data for the other members of the family
(with the exception of II-2) were obtained in a ﬁeld trip during
which history and examination were performed by the same
neurologist. All members of this family underwent an electroen-
cephalography (EEG). All family members gave their informed
consent for this study.
Based on detailed clinical seizure description in the twins, the
diagnosis of TLE was established. Patient II-3, now 30 years old,
denied both febrile seizures (FS) and central nervous system
(CNS) infections. He has had a normal development. He started
having isolated auras characterized by abdominal discomfort, in-
coherent speech, palpitations and blurred vision for one or two
minutes at the age of 13 years. He did not come tomedical atten-
tion until he had his ﬁrst secondarily generalized seizure one
year later. His EEG activity showed burst of theta oscillations in
the temporal lobe. He had complex partial seizures at 19 years
of age. Brain MRI did not show hippocampal sclerosis or any
other anomalies. He is treated with carbamazepine (600 mg/
day) and is seizure-free.
Patient II-4 is treated for TLE since the age of 13 years. His
seizure description was suggestive of mesial temporal origin
(auditory hallucinations, slow ideation, forced thoughts and
Figure 6. Inositol phosphate production in CHO cells expressing human GalR2.
CHO cells were pre-incubated with 1 μCi [3H]-myo-inositol for 24 h before being
stimulated with increasing concentrations of hGal(A39E) in the presence of
100 n of hGal(WT). Data are presented as percent of control (no peptide) and
mean ± SEM of three separate experiments. ***P < 0.001; one-way ANOVA, Tukey
HSD post hoc comparison test.
Figure 4. Inhibition of hGal(WT) stimulation by hGal(A39E) peptide. Serum-
starved Bowes cells expressing GalR1 were pre-incubated for 1 h with hGal
(A39E) peptide (0.1n to 10 μ). Subsequently, cells were stimulated with
100 n hGal(WT). Data are presented as mean ± SEM. Cell index values were
normalized with respect to the cell index at the time of ligand addition and
baseline-corrected by subtracting the cell index obtained with PBS treatment.
Figure 5. Inositol phosphate production in CHO cells expressing human GalR2.
CHO cells were pre-incubated with 1 μCi [3H]-myo-inositol for 24 h before being
stimulated with peptides hGal(WT) or hGal(A39E) at increasing concentrations.
Data are presented as percent of control (no peptide) and mean ± SEM of three
separate experiments. Signiﬁcant level compared to controls: ***P < 0.001; one-
way ANOVA, Tukey HSD post hoc comparison test.
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déjà-vu). The complex partial seizures included loss of aware-
ness and staring. On occasion, they evolved into generalized
tonic-clonic seizures. EEG showed a temporal focus and photo-
sensitivity. Brain MRI analysis did not show hippocampal
sclerosis or other anomalies. He became seizure-free with Leve-
tiracetam (1 g/day).
Samples for screening of galanin mutations
Patients with partial epilepsy
Hundred and eighty-one unrelated individuals of European an-
cestry were admitted to the Epilepsy Unit at Montpellier Univer-
sity Hospital (France) with a diagnosis of FE according to ILAE
Classiﬁcation of 1989 (29). These patients suffered from a severe
form of epilepsy with poor seizure control, although they were
treated by anti-epileptic drugs (AEDs). Diagnosis was based on
patient history, clinical examination, interictal and ictal EEG ana-
lysis carried outwithmonitoring video-EEG, andmagnetic reson-
ance imaging. The study group consisted of patients who
suffered from non-lesional and lesional FE (including vascular
malformation, cortical dysplasia, and nervous system tumor).
These FE patients showed the following distribution of epilepsy
syndromes: 129 patients with TLE (71.4%), 25 patients with front-
al epilepsy (13.7%), 12 patients with frontotemporal epilepsy
(6.6%), 4 patients with temporo-occipital epilepsy (2.2%), 3 pa-
tients with mesial-parietal epilepsy (1.6%), 2 patients with par-
ietal epilepsy (1.1%), 2 patients with parieto-occipital epilepsy
(1.1%), 1 patient with multifocal epilepsy (0.5%), 1 patient with
temporo-parietal epilepsy (0.5%) and 2 patients with undeter-
mined FE (1.1%). This study was approved by the ethics commit-
tee of the University Hospitals of Montpellier.
Thirty-sevenunrelated patientswere recruited in Lyon (n = 14)
(GL, PR), Strasbourg (n = 18) (GR, EH) and Clermont Ferrand (n = 5)
(DSR) through a multicenter research project (Projet Hospitalier
de Recherche Clinique 2007-A00481-52 from the French ministry
of health, coordinator Dr Philippe Ryvlin) that was approved
by the local Ethics Committee (CPP SUD-EST IV). All these
patients had a diagnosis of drug-resistant TLE based on patient
history, clinical examination, interictal and ictal EEG analysis
carried out with monitoring video-EEG, and magnetic resonance
imaging.
Hundred and thirty-one unrelated adult individuals of Euro-
pean ancestry were recruited at the Swiss Epilepsy Center in Zur-
ich (Switzerland). All Individualswere diagnosedwith TLE, two of
which had a bilateral temporal focus.Within this cohort, severity
of phenotypes, subgroups of TLE, familiarity as well as response
to AEDs was diverse. The study was approved by the ethics com-
mittee of the Kanton Zurich.
Hundred and ﬁfty-nine patients with sporadic lateral tem-
poral epilepsy (LTE) were collected as part of a collaborative
study supported by the Genetics Commission of the Italian Lea-
gueAgainst Epilepsy (LICE). Diagnosis of LTEwasmade according
to a clinical history of at least two lifetime seizures with auditory
symptoms such as ringing, humming, sounds, voices, music, or
sudden hearing loss. Sporadic LTE patients were selected accord-
ing to the following inclusion criteria: (i) absence of ﬁrst and se-
cond-degree relatives (siblings, children, parents, grandparents,
aunts and uncles) with epileptic seizures; (ii) absence of neuror-
adiological abnormalities including mesial temporal sclerosis;
(iii) absence of mutations in the LGI1 gene. Exclusion criteria
were an insufﬁcient or doubtful family history and lack of neuroi-
maging data. All patients underwent repeated EEG recordings ac-
cording to the 10–20 International System during wakefulness
and, when possible, during diurnal sleep induced by sleep
deprivation. Each patient underwent high resolution MRI scan
of the brain. This study was approved by LICE and local ethics
committees.
Sixty-four unrelated patients were recruited at the Depart-
ment of Neurology and Epileptology (Tübingen) and Department
of Neuropediatrics (Kiel). Thirty-two children were diagnosed
with focal epilepsies (FE), 18 children with TLE, 10 of which had
abnormal MRI scan (mesial temporal sclerosis (n = 1), cortical
dysplasia (n = 5), 1 with heterotopia (n = 1), arachnoïdal cysts (n =
2), proencephalic cyst temporal (n = 1)). Among these 18 TLE pa-
tients, 11 had normal intelligence, 6 had intellectual disability
and 1 was not assessed. Six patients were diagnosed with frontal
lobe epilepsy (FLE), two of which had abnormalMRI scan (cortical
dysplasia frontal lobe (n = 1), unspeciﬁc gliosis (n = 1). Among
these six FLE patients, one had behavior problems, one had
mild intellectual disability and four had normal intelligence.
Eight children with undetermined focal seizures (unclassiﬁed
focal seizures/secondary generalized seizures), two of which
had abnormal MRI scan [subcortical heterotopias suspected
with hippocampus malrotation (n = 1), unspeciﬁc anomalies (n =
1)]. Among these eight patients, one had behavior problems, one
had mild intellectual disability and six had normal intelligence.
Fourty-nine unrelated Caucasian individuals (mainly of Ger-
man origin) with mesial TLE were recruited as a part of the gen-
etic and pharmacogenetic studies which were approved by the
local Ethics Committee (Department of Neurology and Epileptol-
ogy University of Tübingen). All reported patients gave written
informed consent previous to the study inclusion. The diagnosis
of mesial TLE occurred according to patient history, clinical
examination, EEG analysis and magnetic resonance imaging. A
hippocampal sclerosis was detected in almost all cases (n = 48;
97%). Most of the patients (n = 40, 81%) suffered from refractory
epilepsy, only 14% became seizure-free (n = 5 without surgery
and n = 2 after surgery). In two cases, the outcomewas unknown.
Before study inclusion, the patients had an average of 5.4 (n = 49)
trials of anti-epileptic medication and 6.6 (n = 42) seizures per
month on average.
Exome capture and sequencing
Exome capture from the parents and one of the twins of family
EPI-ORA-AFF (Fig. 1, individuals I-1, I-2 and II-3) was carried out
on 2 μg of genomic DNA extracted from blood using the SureSelect
Human ALL Exon v5 kit (Agilent Technologies). High-throughput
sequencing was performed on a HiSeq2000. Demultiplexed fastq
ﬁles were obtained for each sample using the Illumina CASAVA
v1.8.2 software and processed by our ‘in-house’ pipeline running
on the Vital-IT Center for high-performance computing of the
Swiss Institute of Bioinformatics (SIB; (http://www.vital-it.ch).
Speciﬁcally, Burrows–Wheeler Aligner (BWA) was used to align
the sequencing reads to the human reference genome NCBI
build (GRCh37/hg19). SAMtools was used to remove duplicate
reads. SNVs and small insertions and deletions (INDELs) were
called using bcftools and Pindel 0.2.4, respectively. The minimum
number of reads required for allele calling was set at eight. SNVs
and INDELS variants were then functionally annotated using the
ANNOVAR package.
Identiﬁcation of de novo and recessive variants
Potential pathogenic variants under de novo or recessive models
were identiﬁed using VariantMaster (30). Variants detected in
the proband with Samtools and PINDEL quality scores ≥150 and
≥600, respectively were retained for subsequent analysis. These
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variants were further ﬁltered so as to exclude variants found out-
side of exons or splice sites (±2) and variants with aminimum al-
lele frequency greater than 0.02 in dbSNPv138 (Database of Single
Nucleotide Polymorphism) and/or the Exome Variant Server
(EVS) database. VariantMaster used the raw data (BAM ﬁles) to ro-
bustly estimate the probability of the remaining variants to be
present in the parents and siblings. Variants were classiﬁed as
de novo only if both parents were found to be homozygous for
the reference allele. Homozygote or compound heterozygote var-
iants in the proband that were predicted as damaging by at least
two of the three prediction algorithms used (SIFT, Polyphen2 and
Mutation Taster) were classiﬁed as recessive only if both parents
were carriers and the genotype of the unaffected sister was dif-
ferent from that of the proband. All variants classiﬁed as de
novo or recessive by VariantMaster, were subsequently visually
inspected using the SAMtools text alignment viewer. The re-
maining candidate variants were then validated using Sanger se-
quencing on an ABI 3730xl DNA Analyzer (Applied Biosystems).
Peptide synthesis
Peptides (Human galanin1–30 wild type [hGal(WT)]:GWTLNSA
GYLLGPHAVGNHRSFSDKNGLTS and Human galanin A39E mu-
tant [hGal(A39E)]: GWTLNSEGYLLGPHAVGNHRSFSDKNGLTS)
were synthesized at 0.1 mmol scale on an automated microwave
peptide synthesizer (Biotage® Initiator + Alstra™) using Fmoc
(ﬂuorenylmethyloxycarbonyl) solid-phase peptide synthesis
strategy with HMPB-ChemMatrix 0.4 mmol/g resin as solid
phase to obtain peptide acid. The ﬁrst amino acid was attached
to resin using symmetrical anhydride. All other coupling reac-
tions were carried out using OxymaPure/DIC in DMF with DIEA
as an activator base. The ﬁnal cleavage was performed using
standard protocol (95% TFA/2.5% TIS/2.5% H2O). Peptides were
puriﬁed by reversed-phase HPLC using BioBasic C-8 column
(Thermo Scientiﬁc, Sweden) and a gradient of 20–80% aceto-
nitrile/water containing 0.1% TFA. The identity of peptides
was analyzed by MALDI-TOF mass spectrometry Voyager-DE
STR (Applied Biosystems) in positive linear mode using α-
cyano-4-hydroxycinnamic acid as matrix.
Galanin-receptor binding assays
Cells for 125I-galanin-receptor displacement studies were seeded
in 150-mm dishes and cultured 3–4 days until conﬂuent. Cell
dishes were washed and scraped into phosphate-buffered saline
(PBS) and centrifuged twice at 4°C, 3000 g for 5 min. The pellet
was re-suspended in assay buffer (20 m HEPES, 5 m MgCl2,
pH 7.4) supplemented with EDTA (5 m EDTA) and incubated
on ice for 45 min before centrifugation at 4°C, 8500 g for 15 min.
After washing, the pellet was re-suspended in assay buffer sup-
plemented with 1% protease inhibitor cocktail (Sigma–Aldrich,
St. Louis, MO, USA) to a protein concentration of 1 mg/ml. Protein
concentration was determined according to Lowry (BioRad,
Stockholm, Sweden). Displacement studies on cell membranes
were performed in a ﬁnal volume of 200 μl, containing 0.15 n
porcine-[125I]-galanin (2200 Ci/mmol; Perkin–Elmer Life Science,
Boston, MA, USA), 30 μg cell membrane and various concentra-
tions of peptide (10−5–10−9M). Peptide solutions were made in
assay buffer supplemented with 0.3% bovine serum albumin
(BSA). Samples were shaken at 37°C for 30 min and ﬁltered
through a MultiScreen-FB ﬁlter plate (Millipore, Billerica, MA,
USA) pre-soaked in 0.3% polyethylenimine solution (Sigma–Al-
drich). The ﬁlters were washed thrice with assay buffer and the
retained radioactivity was determined in a β-counter (Tri-Carb Li-
quid Scintillation Analyzer, model 2500 TR; Packard Instrument
Company, Meriden, CT, USA) using OptiPhase Supermix Cocktail
(Perkin–Elmer Life Science, Boston, MA, USA) as scintillation
ﬂuid. IC50 values for the peptides were calculated using Prism
5.0 (GraphPad Software Inc., San Diego, CA, USA) and converted
into Ki values using the equation of Cheng–Prusoff (31).
xCELLigence cellular impedance assay
The impedance-based readout used by the xCELLigence System
(Roche Applied Science) is based on the principle that the adhe-
sion of cultured cells directly onto microelectrodes induces
changes in the local ionic environment at the electrode/solution
interface, conferring an increase in electrode impedance. As a re-
sult, any changes in cell physiological properties that modulate
the physical contact between cell and electrode will be reﬂected
by changes in the measured impedance, deﬁned by the cell
index variable. xCELLigence System can be used for functional
screening of G-protein-coupled receptors (GPCRs) activity,
based on its ability to modulate the actin cytoskeleton and cell
adhesion (32–34). Bowes cells expressing GalR1 were seeded at
20 000 cells per well on 96-well E-Plates (ACEA Biosciences Inc.)
and placed on the Real-time xCELLigence Cell Analyzer (Roche
Applied Science) platform at 37°C and 5% CO2. After 24 h incuba-
tion, growth media was changed for assay buffer (HBSS contain-
ing 0.1% BSA). Three hours later, hGal(A39E) peptide was added
(0.1 n to 10 µ), after 1 h incubation, hGal(WT) was added at
100 n. The xCELLigence System was employed to measure
changes in cellular impedance following ligand stimulation. Re-
sulting dose–response relationships were plotted usingmean va-
lues from four replicates. Cell index values were normalized by
dividing the cell index at the time of ligand addition and base-
line-corrected by subtracting the cell index obtained with PBS
treatment. Data analysiswas donewith built-in xCELLigence Sys-
tem software and presented with GraphPad Prism.
Inositol phosphate accumulation assay
CHO cells stably expressing humanGalR2were seeded in 12-well
plates and cultured until conﬂuent. Then cells were incubated
24 h with 1 μCi [3H]-myo-inositol in M-199 medium containing
100 U ml−1 penicillin and 100 μg ml−1 streptomycin. CHO GalR2
cells were washed twice with HEPES Krebs Ringer (HKR) buffer
(5 m HEPES, 137 m NaCl, 2.68 m KCl, 2.05 m MgCl2,
1.8 m CaCl2, 1 g/l glucose, pH7.4) followed by 10 min pre-incu-
bation in 800 μl HKR buffer with 10 m LiCl at 37°C. hGal(A39E)
peptide (10−5–10−8 M) with or without hGal(WT) (10−7 M) was
added to a ﬁnal volume of 1000 μl and incubated for 60 min at
37°C. The reaction was terminated by addition of 200 μl ice cold
20% perchloric acid followed for 10 min followed by the addition
of 1.5 M KOH/75 m HEPES (pH7). Anion exchange chromatog-
raphy was performed over 1 cm 50:50 Dowex (AG 1-X8 Resin,
200– 400mesh formate; BioRad, Hercules, CA, USA). The columns
were washed with 5 ml distilled water before the IPs were eluted
with 5 ml of 0.1  formic acid/1.2  ammonium formate. Radio-
activity of the eluate was determined using scintillation count-
ing in a β-counter (Tri-Carb Liquid Scintillation Analyzer,
model 2500 TR, Packard Instrument Company, Meriden, CT,
USA) using Utima Flo AF (Perkin–Elmer Life Science, Boston,
MA, USA) as scintillation ﬂuid. Each sample was normalized
against the total count obtained before anion exchange
chromatography.
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